课题基金 / 基金详情

PAMIDRONATE ON BONE DENSITY IN PATIENTS WITH CYSTIC FIBROSIS

PAMIDRONATE ON BONE DENSITY IN PATIENTS WITH CYSTIC FIBROSIS
帕米膦酸钠对囊性纤维化患者骨密度的影响
批准号：
6297315
负责人：
ROBERT M ARIS
金额：
$0.02万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6297315
关键词：
bone density clinical research cystic fibrosis drug screening /evaluation human subject human therapy evaluation osteoporosis phosphonate skeletal disorder chemotherapy skeletal pharmacology

项目摘要

项目成果

ROBERT M ARIS的其他基金

相似基金

相关文献

中文摘要
翻译
假设帕米膦酸盐，一种抑制骨吸收的双膦酸盐药物，将有效逆转骨脱矿和预防CF患者的特征。 我们计划在一组已经接受或正在等待肺移植的CF患者中检验这一假设，因为该队列可能代表骨质疏松症的最坏情况，因此，从治疗中显著获益的机会很高。
英文摘要
The hypothesis is that pamidronate, a biphosphonate drug that inhibits bone resorption, will be efficacious in reversing bone demineralization and preventing features in CF patients. We plan to test this hypothesis in a group of CF patients who have undergone or are awaiting lung transplanation because this cohort likely represent a worst-case scenario of osteoporosis and, therefore, the chances of significant benefit from therapy are high.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bisphosphonates on Bone Mineral Density in Patients with Cystic Fibrosis
The Effects of Alendronate on Bone Metabolism in Patients with CF
EFFECTS OF ALENDRONATE ON BONE METABOLISM IN PATIENTS WITH CYSTIC FIBROSIS
PAMIDRONATE ON BONE DENSITY IN PATIENTS WITH CYSTIC FIBROSIS
海外基金